This is slated as bad timing, but it could be a good thing in reality when you look at the choices and there were a couple other investors and now it's all on their shoulders. Only 7 venture backed companies have gone public this year, 4 of which were biotech, compared to 86 start up companies in 2007. Press release with substantial order in the UK. 
BD
There is a tiny shred of good news for Lehman Brothers: one of the investments of its Healthcare Venture Capital arm, a biotech company called Fluidigm, is set to go public this week. Then again, that might not be such good news. It is the worst week the market has seen in years, in a year that has been difficult for start-ups that have gone public. This is terrible timing for this company, said Scott Sweet, senior managing partner at I.P.O. Boutique, an I.P.O. research and advisory firm for individuals and hedge funds. Fluidigm hopes to make an initial public offering on Thursday, underwritten by Morgan Stanley. Shares will be priced at around $14 to $16 and the company plans to raise $70 million to $85 million. In addition to Lehman, venture investors included Versant Ventures, Euclid SR Partners and Alloy Ventures.
A Lehman-Backed Biotech Braves the Markets - Bits Blog - NYTimes.com
0 comments :
Post a Comment